Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$9.46

-0.34 (-3.47%)

08:29
11/06/18
11/06
08:29
11/06/18
08:29

Iovance says new cohort of 80-100 patients in C-144-01 will be enrolled

Iovance Biotherapeutics said this morning in a press release, "As previously reported, an End of Phase 2 meeting with the FDA was held. During this meeting, the FDA acknowledged the potential acceptability of a single-arm cohort for registration. FDA has further acknowledged that conduct of a randomized Phase 3 trial may not be feasible in its intended population of advanced melanoma patients who have been treated with at least one systemic therapy including a PD-1 blocking antibody and if BRAF V600 mutation positive, a BRAF inhibitor or BRAF inhibitor with MEK inhibitor and is not required for initial registration of lifileucel. Literature suggests that available care for these patients offers approximately 10% ORR. A new cohort of 80-100 patients in C-144-01 will be enrolled with a prospective definition of the primary endpoint of ORR to be read out by a Blinded Independent Review Committee to support registration of lifileucel. This new cohort, which the company refers to as Cohort 4, will be initiated in early 2019 and is expected to be fully enrolled by late 2019/early 2020. BLA submission to FDA is expected in the second half of 2020."

  • 06

    Nov

IOVA Iovance Biotherapeutics
$9.46

-0.34 (-3.47%)

09/13/18
JEFF
09/13/18
NO CHANGE
Target $31
JEFF
Buy
Feedback on Moffitt TIL study appears positive, says Jefferies
Jefferies analyst Biren Amin hosted a call with an oncologist at Moffitt Cancer Center to review the initial data from this first non-small cell lung cancer tumor infiltrating lymphocytes study. The doctor highlighted the large unmet need in NSCLC patients who failed to respond to anti-PD-1 therapy and feels the 100% disease control rate achieved in the first eight refractory patients to nivo is promising, Amin tells investors in a research note. Further, the oncologist believes the limited duration of response could improve in a second NSCLC study incorporating key "biomarkers," the analyst points out. Amin believes Iovance Biotherapeutics could incorporate some of these key learnings into its two Phase I/II NSCLC studies. The analyst keeps a Buy rating on Iovance with a $31 price target.
09/25/18
COWN
09/25/18
NO CHANGE
COWN
Outperform
Iovance Biotherapeutics weakness a buying opportunity, says Cowen
Cowen analyst Boris Peaker said the recent weakness in Iovance is a buying opportunity. The analyst noted the company's results from the Moffitt-run study of TILS in NSCLC were deemed mild and somewhat disappointing. He believes the data has no read-through to the ongoing melanoma trial, making the weakness an attractive entry point. Peaker reiterated his Outperform rating on Iovance shares.
10/12/18
OPCO
10/12/18
NO CHANGE
Target $25
OPCO
Outperform
Iovance Biotherapeutics price target raised to $25 from $22 at Oppenheimer
Oppenheimer analyst Mark Breidenbach reiterated an Outperform rating on Iovance Biotherapeutics and raised his price target to $25 from $22 citing recent positive clinical updates for its tumor infiltrating lymphocyte product for melanoma and the outcome of discussions with the FDA regarding the regulatory pathway forward.
10/12/18
HCWC
10/12/18
NO CHANGE
HCWC
Iovance Biotherapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics and raised his price target on shares to $26 from $22, following the outcome of the end-of-Phase 2 meeting with the FDA regarding lead candidate LN-144. Pantginis called the interactions with the FDA "successful," and believes that Iovance will "further pursue its discussion with the agency in order to find the best path forward for LN-144 followed by assets across multiple indications." Additionally, the analyst reiterated his belief that Iovance is a compelling takeout candidate, and added that the company's cash resources provide strong leverage in any discussions.

TODAY'S FREE FLY STORIES

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.43

-0.07 (-0.08%)

15:10
02/21/19
02/21
15:10
02/21/19
15:10
Options
Far downside ratio spread opened in High Yield Bond Fund »

Far downside ratio spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWDP

DowDuPont

$55.19

-1.06 (-1.88%)

15:06
02/21/19
02/21
15:06
02/21/19
15:06
Hot Stocks
Corteva Agriscience announces U.S. launch of Enlist E3 soybeans »

Corteva Agriscience, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 27

    Feb

  • 04

    Mar

  • 04

    Mar

  • 13

    Mar

  • 28

    May

EXAS

Exact Sciences

$82.81

-0.79 (-0.94%)

15:04
02/21/19
02/21
15:04
02/21/19
15:04
Options
EXACT Sciences options imply 15.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 18

    May

GE

General Electric

$10.05

-0.055 (-0.54%)

15:00
02/21/19
02/21
15:00
02/21/19
15:00
Options
100K GE Mar 8th 9 puts bought for 5c with shares flat at $10.10 »

100K GE Mar 8th 9 puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$43.81

-1.35 (-2.99%)

14:59
02/21/19
02/21
14:59
02/21/19
14:59
Periodicals
Anadarko says 4 injured in attack at Mozambique LNG project, Bloomberg reports »

Anadarko Petroleum said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

  • 22

    May

ALB

Albemarle

$88.17

5.35 (6.46%)

14:54
02/21/19
02/21
14:54
02/21/19
14:54
Recommendations
Albemarle analyst commentary  »

Albemarle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 27

    Feb

PBR

Petrobras

$16.70

-0.01 (-0.06%)

14:53
02/21/19
02/21
14:53
02/21/19
14:53
Periodicals
Brazil minister says Petrobras TOR auction may occur in late 2019, Reuters says »

Brazil's Energy and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TI

Telecom Italia

$5.92

-0.12 (-1.99%)

14:51
02/21/19
02/21
14:51
02/21/19
14:51
Hot Stocks
Telecom Italia sees organic group EBITDA to decrease low single digit in 2019 »

TIM's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TSU

Tim Participacoes

$16.30

0.03 (0.18%)

14:50
02/21/19
02/21
14:50
02/21/19
14:50
Hot Stocks
Breaking Hot Stocks news story on Tim Participacoes »

TIM Participacoes trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$51.60

-2.03 (-3.79%)

14:49
02/21/19
02/21
14:49
02/21/19
14:49
Options
Roku options imply 18.8% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

, QUAD

Quad/Graphics

$15.85

-0.42 (-2.58%)

14:47
02/21/19
02/21
14:47
02/21/19
14:47
Conference/Events
Quad/Graphics to host special shareholder meeting »

Special Shareholder…

LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

QUAD

Quad/Graphics

$15.85

-0.42 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

FB

Facebook

$160.21

-2.4 (-1.48%)

14:46
02/21/19
02/21
14:46
02/21/19
14:46
Periodicals
Kids advocacy groups urge FTC to probe Facebook over game purchases, Adweek says »

Childrens' advocacy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

QUAD

Quad/Graphics

$15.80

-0.47 (-2.89%)

, LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

14:41
02/21/19
02/21
14:41
02/21/19
14:41
Conference/Events
LSC Communications to host special shareholder meeting »

Special Shareholder…

QUAD

Quad/Graphics

$15.80

-0.47 (-2.89%)

LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

GIL

Gildan Activewear

$34.04

-0.13 (-0.38%)

14:37
02/21/19
02/21
14:37
02/21/19
14:37
Downgrade
Gildan Activewear rating change  »

Gildan Activewear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TSU

Tim Participacoes

$16.30

0.03 (0.18%)

14:37
02/21/19
02/21
14:37
02/21/19
14:37
Earnings
Tim Participacoes releases guidance for 2019-2021 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip

$32.55

-1.24 (-3.67%)

14:35
02/21/19
02/21
14:35
02/21/19
14:35
Options
Ctrip.com put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 04

    Mar

  • 20

    Mar

NAII

Natural Alternatives International

$11.15

(0.00%)

14:34
02/21/19
02/21
14:34
02/21/19
14:34
Hot Stocks
Natural Alternatives International hires David Brook for sports nutrition unit »

Natural Alternatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

14:24
02/21/19
02/21
14:24
02/21/19
14:24
Hot Stocks
Nintendo of America president, COO Reggie Fils-Aime to retire »

Nintendo announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.83

-0.21 (-1.40%)

14:23
02/21/19
02/21
14:23
02/21/19
14:23
Hot Stocks
Fiat Chrysler to propose EUR0.65 per share dividend »

Fiat Chrysler Automobiles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$43.43

-0.32 (-0.73%)

14:20
02/21/19
02/21
14:20
02/21/19
14:20
Options
20K iShares Brazil Fund Mar 44 - 46 call spreads sold at 60c »

20K iShares Brazil Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
02/21/19
02/21
14:17
02/21/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/21/19
02/21
14:16
02/21/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$34.55

-1.08 (-3.03%)

14:15
02/21/19
02/21
14:15
02/21/19
14:15
Options
Baozun put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THRM

Gentherm

$44.16

1.3 (3.03%)

14:11
02/21/19
02/21
14:11
02/21/19
14:11
Downgrade
Gentherm rating change  »

Craig-Hallum downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

PTC

PTC

$91.88

0.04 (0.04%)

14:08
02/21/19
02/21
14:08
02/21/19
14:08
Hot Stocks
New offering from PTC and ANSYS brings real-time simulation to design engineers »

PTC announced the release…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 14

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.